A clinical trial in China of Gilead’s Remdesivir is cut short due to disappointing expectations, prompting a sharp response from Gilead explaining the trial was cut short due to the low amount of trial participants.
Gilead’s stock takes a minor hit.
This comment may be in violation of our guidelines. You can still post it, but it will remain hidden until reviewed by one of our moderators.
This comment may be a reaction with little substance. It's at risk of being ranked lower than other comments.
Quality over quantity. You've hit our limit for comments posted. Please try again in an hour.